| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.081 | 0.08 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.08 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.08 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.058 | 0.08 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.092 | 0.08 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.09 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.09 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | -0.092 | 0.09 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |